Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Gilead Sciences, Inc. : FDA Panel Backs Gilead's HIV 'Quad' Medicine

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/11/2012 | 09:06pm CEST
   By Jennifer Corbett Dooren 
   Of  
 

A federal advisory panel Friday backed an experimental Gilead Sciences Inc. (GILD) HIV medicine known as the Quad.

The company is seeking approval from the Food and Drug Administration to market the product, which combines four active ingredients into one pill, meant to be taken once daily.

The medicine was reviewed on Friday by the agency's antiviral drugs advisory panel, which is made up of non-FDA medical experts. The panel voted 13 to 1 on a question that asked if the submitted clinical data supported approval of the drug. The panel vote amounts to a recommendation that the FDA approve the drug. The agency usually follows panel recommendations but isn't required to. The FDA is expected to make a decision by the end of August.

Quad is a combination of four active ingredients in one pill. It combines Gilead's double-drug Truvada, the drug elvitegravir and an agent that boosts blood levels of certain HIV drugs, cobicistat.

Gilead is hoping that the one-pill, once-daily Quad regimen will provide more convenience to HIV patients, many of whom now take multiple pills for treatment. Some analysts think it could become a blockbuster seller.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
06/26 GILEAD SCIENCES : Featured Company News - Gilead's Vosevi Receives Positive Opin..
06/24 MERCK AND : Gilead among drug stocks buoyed by Trumps healthcare plans
06/23 GILEAD SCIENCES : White House Plan To Reduce Drug Prices… Is To EXTEND Pa..
06/23 GILEAD SCIENCES : European CHMP Adopts Positive Opinion for Gilead’s Vosev..
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/22 GILEAD SCIENCES : Submits New Drug Application to U.S. Food and Drug Administrat..
06/22 GILEAD SCIENCES : Patent Issued for Methods for Preparing Anti-Viral Nucleotide ..
06/21 GILEAD SCIENCES : Biotech Industry Showing Signs of a Revival in 2017: Today's R..
06/19 GILEAD SCIENCES : Receives Approval in Canada for VEMLIDY™ (Tenofovir Alaf..
06/16 GILEAD SCIENCES : submits drug application to FDA for HIV treatment
More news
Sector news : Bio Therapeutic Drugs
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
06/14 JOHNSON & JOHNSON : flu drug succeeds in mid-stage trial
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
06/27 TIGENIX : This Stem Cell Pioneer Is Up 40% Since IPO With More Upside To Come
06/26 THE OPIOID ABUSE EPIDEMIC : What's The Investment Angle?
06/26 BIOTECH BOOM! : Overview And Company-By-Company Review
06/26 Recent Stock Purchase June 2017
06/26 Monday Market Movement - Hedging For The Holidays
Advertisement
Financials ($)
Sales 2017 24 666 M
EBIT 2017 15 040 M
Net income 2017 9 730 M
Debt 2017 5 653 M
Yield 2017 2,98%
P/E ratio 2017 9,52
P/E ratio 2018 10,54
EV / Sales 2017 3,97x
EV / Sales 2018 4,39x
Capitalization 92 320 M
More Financials
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 77,7 $
Spread / Average Target 9,9%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES-1.34%92 320
AMGEN16.85%125 643
CELGENE CORPORATION13.05%102 171
REGENERON PHARMACEUTIC..40.54%53 371
VERTEX PHARMACEUTICALS75.42%32 187
ACTELION23.13%30 672
More Results